3.3. CD19-ReTARGTPR Selectively Redirects the Cytotoxic Activity of Anti-CMVpp65 CD8pos T Cells Towards CD19pos Cancer Cell Lines and Patient-Derived CLL Cells. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.